Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Allergan Plc (AGN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 50,343,904
  • Shares Outstanding, K 337,290
  • Annual Sales, $ 15,941 M
  • Annual Income, $ -4,125,500 K
  • 36-Month Beta 1.32
  • Price/Sales 3.20
  • Price/Cash Flow 3.72
  • Price/Book 0.71

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 15 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/18
See More
  • Average Estimate 4.12
  • Number of Estimates 17
  • High Estimate 4.33
  • Low Estimate 3.83
  • Prior Year 4.86
  • Growth Rate Est. (year over year) -15.23%

Price Performance

See More
Period Period Low Period High Performance
1-Month
125.84 +21.98%
on 12/26/18
154.15 -0.42%
on 01/16/19
+5.27 (+3.56%)
since 12/14/18
3-Month
125.84 +21.98%
on 12/26/18
192.69 -20.34%
on 10/17/18
-34.49 (-18.35%)
since 10/16/18
52-Week
125.84 +21.98%
on 12/26/18
197.00 -22.08%
on 10/03/18
-25.16 (-14.08%)
since 01/16/18

Most Recent Stories

More News
Sperling Dermatology officially recognized as Number 1 CoolSculpting provider in NJ, number 4 in country by CoolSculpting parent company Allergan

Sperling Dermatology named number 1 CoolSculpting provider in NJ, number 4 in the USA; blends best-in-class sales, marketing, and technology systems together to become one of fastest growing CoolSculpting...

AGN : 153.52 (+0.54%)
Ironwood's (IRWD) Linzess Gets Approval in China for IBS-C

Ironwood Pharmaceuticals (IRWD) gets approval for Linzess in China for the treatment of adults with IBS-C

MYL : 29.27 (-0.27%)
IRWD : 13.16 (+1.00%)
AZN : 35.74 (-1.02%)
AGN : 153.52 (+0.54%)
Asia-Pacific Nonalcoholic Steatohepatitis Therapeutics Markets Report 2018-2024 Featuring Key Players - Allergan, Galmed, Genfit, Gilead, Intercept Pharmaceuticals & Zydus

The "Nonalcoholic Steatohepatitis Therapeutics in Asia-Pacific Markets to 2024 - Launch of NASH-Specific Premium Products and Rising Prevalence to Drive the Market" report has been added to ResearchAndMarkets.com's...

AGN : 153.52 (+0.54%)
SHAREHOLDER ALERT: GS XRAY NVDA AGN: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines

The Law Offices of Vincent Wong announce that class actions have commenced on behalf of shareholders of the following companies. If you suffered a loss you have until the lead plaintiff deadline to request...

NVDA : 149.65 (-0.15%)
AGN : 153.52 (+0.54%)
XRAY : 40.33 (+1.31%)
GS : 194.00 (+7.83%)
Medical Aesthetics Market Forecast to Touch US$ 19 Billion By 2023

New York, January 15, 2018: The scope of the report includes a detailed study of global and regional markets on Global with the reasons given for variations in the growth of the industry in certain regions....

VRX.TO : 30.80 (-3.33%)
ZLTQ : 56.48 (unch)
AGN : 153.52 (+0.54%)
CYNO : 66.15 (+0.23%)
ELOS : 11.00 (unch)
NSRGF : 84.5400 (+0.27%)
CoolSculpting® and Sonja Morgan Partner To Get Real About Self-Care

Television personality on Bravo's "The Real Housewives of New York City", philanthropist, fashion lifestyle entrepreneur and mom, Sonja Morgan, is partnering with CoolSculpting, owned by Allergan plc (NYSE:...

AGN : 153.52 (+0.54%)
CLASS ACTION UPDATE for NVDA and AGN: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders

Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have...

NVDA : 149.65 (-0.15%)
AGN : 153.52 (+0.54%)
SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Allergan plc (AGN) & Lead Plaintiff Deadline: February 19, 2019

Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against Allergan plc ("Allergan" or the "Company") (NYSE: AGN) and certain of its...

AGN : 153.52 (+0.54%)
The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of XRAY, NVDA and AGN

The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. If you suffered a loss you have until the lead plaintiff deadline to request...

NVDA : 149.65 (-0.15%)
AGN : 153.52 (+0.54%)
XRAY : 40.33 (+1.31%)
ALLERGAN SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Allergan plc. - AGN

ClaimsFiler, a FREE shareholder information service, reminds investors that they have until February 19, 2019 to file lead plaintiff applications in a securities class action lawsuit against Allergan plc....

AGN : 153.52 (+0.54%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 16% Buy with a Average short term outlook on maintaining the current direction.

Longer term, the trend strength is Minimum.

The market is in highly overbought territory. Beware of a trend reversal.

See More Share

Trade AGN with:

Business Summary

Allergan, Inc. is a healthcare company. It focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets. Allergan...

See More

Key Turning Points

2nd Resistance Point 156.48
1st Resistance Point 154.58
Last Price 153.52
1st Support Level 150.19
2nd Support Level 147.70

See More

52-Week High 197.00
Fibonacci 61.8% 169.82
Fibonacci 50% 161.42
Last Price 153.52
Fibonacci 38.2% 153.02
52-Week Low 125.84

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar